Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Distinctive roles of syntaxin binding protein 4 and its action target, TP63, in lung squamous cell carcinoma: a theranostic study for the precision medicine

Fig. 3

Ingenuity pathway analysis (IPA) using the knowledge database. Probable interrelations (a) and canonical pathways (b) of 7 exploratory therapeutic targets were assessed by IPA. STXBP4 acts as an up-stream regulator of TP63 (ΔNp63) and subsequently KDR (VEGFR2) via TP63, whereas the action pathway of STXBP4 was independent from those of the other 4 exploratory target genes (TP53, TUBB3, CD274 and STMN1)

Back to article page